

Treatment Decisions In Metastatic EGFRm NSCLC:

Maximizing Benefit From First-line Treatment to Progression And Beyond

12 April 2019 | 16:30-17:30 | Room A | Palexpo, Geneva, Switzerland

AGENDA

Welcome and Program Overview

Considerations for first-line treatment selection for patients with metastatic EGFRm NSCLC

What do we know?

First-line osimertinib treatment and mechanisms of acquired resistance

What's next?

Clinical management of patients with progression on first-line osimertinib

How do we manage patients who need second-line therapy?

Clinical practice approach to therapy selection

FACULTY PANELISTS



Marina Garassino MD

Istituto Nazionale
dei Tumori
Milan, Italy



**Vassiliki
Papadimitrakopoulou MD**

MD Anderson Cancer Center
Houston, Texas, USA



Niels Reinmuth MD

Asklepios Fachkliniken
München-Gauting
Gauting, Germany

AstraZeneca's Commitment To Sustainability*



Environmental Protection

Putting the planet at the
heart of human health

*For more information, please visit the AstraZeneca website